Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A new era in anticancer peptide vaccines.
Perez SA, von Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis CN. Perez SA, et al. Among authors: von hofe e. Cancer. 2010 May 1;116(9):2071-80. doi: 10.1002/cncr.24988. Cancer. 2010. PMID: 20187092 Free article. Review.
Ii-Key/HER-2/neu(776-790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors.
Sotiriadou NN, Kallinteris NL, Gritzapis AD, Voutsas IF, Papamichail M, von Hofe E, Humphreys RE, Pavlis T, Perez SA, Baxevanis CN. Sotiriadou NN, et al. Among authors: von hofe e. Cancer Immunol Immunother. 2007 May;56(5):601-13. doi: 10.1007/s00262-006-0213-z. Epub 2006 Sep 8. Cancer Immunol Immunother. 2007. PMID: 16960693 Free PMC article.
Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA, Kallinteris NL, Bisias S, Tzonis PK, Georgakopoulou K, Varla-Leftherioti M, Papamichail M, Thanos A, von Hofe E, Baxevanis CN. Perez SA, et al. Among authors: von hofe e. Clin Cancer Res. 2010 Jul 1;16(13):3495-506. doi: 10.1158/1078-0432.CCR-10-0085. Epub 2010 May 13. Clin Cancer Res. 2010. PMID: 20466887 Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: von hofe e. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
54 results